These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23410661)

  • 1. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
    Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
    Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
    Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
    Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.
    Natsumeda M; Igarashi H; Nomura T; Ogura R; Tsukamoto Y; Kobayashi T; Aoki H; Okamoto K; Kakita A; Takahashi H; Nakada T; Fujii Y
    Acta Neuropathol Commun; 2014 Nov; 2():158. PubMed ID: 25376594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
    Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue 2-Hydroxyglutarate as a Biomarker for
    Sim HW; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX
    Clin Cancer Res; 2019 Jun; 25(11):3366-3373. PubMed ID: 30777876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2019 Jan; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
    Andronesi OC; Kim GS; Gerstner E; Batchelor T; Tzika AA; Fantin VR; Vander Heiden MG; Sorensen AG
    Sci Transl Med; 2012 Jan; 4(116):116ra4. PubMed ID: 22238332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.
    Figarella-Branger D; Bouvier C; de Paula AM; Mokhtari K; Colin C; Loundou A; Chinot O; Metellus P
    J Neurooncol; 2012 Nov; 110(2):205-13. PubMed ID: 22890969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
    Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM
    Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
    J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
    Pusch S; Schweizer L; Beck AC; Lehmler JM; Weissert S; Balss J; Miller AK; von Deimling A
    Acta Neuropathol Commun; 2014 Feb; 2():19. PubMed ID: 24529257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.
    Choi C; Ganji SK; DeBerardinis RJ; Hatanpaa KJ; Rakheja D; Kovacs Z; Yang XL; Mashimo T; Raisanen JM; Marin-Valencia I; Pascual JM; Madden CJ; Mickey BE; Malloy CR; Bachoo RM; Maher EA
    Nat Med; 2012 Jan; 18(4):624-9. PubMed ID: 22281806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.
    Capper D; Simon M; Langhans CD; Okun JG; Tonn JC; Weller M; von Deimling A; Hartmann C;
    Int J Cancer; 2012 Aug; 131(3):766-8. PubMed ID: 21913188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
    Fathi AT; Nahed BV; Wander SA; Iafrate AJ; Borger DR; Hu R; Thabet A; Cahill DP; Perry AM; Joseph CP; Muzikansky A; Chi AS
    Oncologist; 2016 Feb; 21(2):214-9. PubMed ID: 26834160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.
    Juratli TA; Kirsch M; Robel K; Soucek S; Geiger K; von Kummer R; Schackert G; Krex D
    J Neurooncol; 2012 Jul; 108(3):403-10. PubMed ID: 22410704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
    Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
    World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.